Project Grant R01HL181085
Award Date 7/1/26
Completion Date 12/31/27
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a $249,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for the period June 1, 2026 through April 30, 2029. This award funds research to characterize genetic variants associated with doxorubicin-induced cardiotoxicity (DIC), a life-threatening side effect of chemotherapy used to treat breast cancer and pediatric cancers. The research leverages...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant of $1,102,500 under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026 through June 30, 2033. The award funds an NIH R35 research program investigating the molecular mechanisms of immune suppression in Acute Respiratory Distress Syndrome (ARDS). The research focuses on discovering and characterizing F-box proteins as immunosuppressive...
- Federal Grant Award Summary The Ohio State University has been awarded $121,658 under the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) for a two-year Project Grant effective June 1, 2026, through May 31, 2028. The award funds research titled "Decoding the Role of Adipocyte-Derived Extracellular Vesicle Cargo in Modulating Distal Inflammation," which investigates mechanisms linking obesity-related adipose tissue inflammation to...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University $1.4 million under the Cardiovascular Diseases Research program (CFDA 93.837) on August 18, 2025, for research into the biological basis of cardiac thick filament regulation. The project, which extends through May 31, 2029, investigates the molecular mechanisms by which cardiac myosin and cardiac myosin-binding protein-C (cMyBP-C) regulate force generation in cardiac muscle. The...
- Federal Project Grant Award Summary The Ohio State University Office of Sponsored Programs received a $156,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective February 19, 2026, with a completion date of September 29, 2026. This research grant funds an investigative project titled "The Role of NCOA4-Mediated Ferritinophagy in Ozone-Induced Pulmonary Ferroptosis," which addresses...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant totaling $694,466 under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanistic role of mitochondrial BK (mitoBK) channels in cardiac physiology and protection against pathological cardiac hypertrophy. The award, obligated on September 5, 2025, with completion targeted for June 30, 2029, funds research aimed at establishing the...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $1.597 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion targeted for December 31, 2027. The research project, conducted in Chicago, Illinois, investigates mechanisms to improve cardiac allograft survival in heart transplant recipients by modulating...
- Federal Grant Award Summary The Research Institute at Nationwide Children's Hospital received a $775,114 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 12, 2026, with completion targeted for February 28, 2030. The award funds preclinical evaluation of a tissue-engineered vascular graft (TEVG) designed for congenital heart surgery. The TEVG is manufactured by seeding autologous cells onto a...
- Federal Grant Award Summary Oklahoma State University received a $552,649 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026 through June 30, 2029. The award supports research investigating the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) in cardiac regeneration and cardiomyocyte proliferation. The research aims to elucidate metabolic mechanisms by which...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $684,570 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with a completion date of April 30, 2030. The project delivers translational research and development of a bioengineered mitochondrial therapy platform designed to address endothelial injury in vascular surgery. The research platform...